Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in Shanghai Teresa Healthcare, with price specifics not disclosed. The deal grants Immuno Cure control of Teresa’s proprietary electroporation (EP) technology and related devices in China.
Deal Structure and Shareholder Details
Beyond the acquisition, Immuno Cure is paying in cash and shares, with Teresa shareholders allowed to swap for about a 1.5% equity holding in Immuno Cure. Teresa’s founding scientist, Professor Xu Yuhong, retains her 7.4% direct holding in Teresa. The deal specifics were not disclosed.
Electroporation Technology and Applications
EP technology involves a device that delivers electrical pulses into the skin of patients to facilitate the penetration of DNA vaccines through the cell membrane. The technology has already won approval in China for the administration of DNA vaccines. Immuno Cure and Teresa had previously partnered on the technology, which is a key component of Immuno Cure’s DNA vaccine delivery strategy.
Company Backgrounds
Teresa Healthcare, an innovative medical device company established in 2004, focuses on electro immunotherapies and rehabilitation therapies. The firm’s EP technology was licensed from Shanghai Jiao Tong University under the National 863 Project. The EP delivery method has been found to be safe and efficacious, used by over 10,000 patients, and is in over 30 hospitals for the administration of DNA medicine in human trial subjects. Immuno Cure, meanwhile, has two PD-1-enhanced DNA vaccines currently under Phase I study for the prevention of COVID-19 and therapeutic cure of HIV/AIDS.
Future Outlook
The acquisition of a controlling stake in Shanghai Teresa Healthcare underscores Immuno Cure BioTech’s commitment to advancing its DNA vaccine delivery strategy. By integrating Teresa’s EP technology, Immuno Cure aims to enhance its capabilities in delivering innovative therapies, ultimately contributing to advancements in global healthcare.-Fineline Info & Tech
